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Objectives. This study evaluated the long-term clinical outcome
of successful repeat percutaneous intervention after in-stent re-
stenosis.
Background. Recurrence of symptoms and angiographic resten-
osis after stent implantation are observed in 15% to 35% of cases.
Repeat percutaneous treatment for in-stent restenosis has been
shown to be safe, with high immediate success, but little is known
about the long-term clinical outcome.
Methods. Clinical follow-up (minimum 9 months) was obtained
in a consecutive series of 124 patients (127 vessels) presenting
with stent restenosis who were successfully treated with repeat
percutaneous intervention.
Results. Clinical follow-up was obtained in all 124 patients at a
mean [6SD] of 27.4 6 14.7 months (range 9 to 66); a stress test
was available in 88 patients (71%). Recurrence of clinical events
occurred in 25 patients (20%) and included death from any cause
in 2 patients (2%), target vessel revascularization in 14 (11%),
myocardial infarction in 1 (1%) and positive stress test results or
recurrence of symptoms (Canadian Cardiovascular Society class I
to IV) treated medically in 8 (6%). Cumulative event-free survival
at 12 and 24 months was 86.2% and 80.7%, respectively. Signifi-
cant predictive factors of recurrence of clinical events were repeat
intervention in saphenous vein grafts, multivessel disease, low
ejection fraction and a <23-month interval between stent implan-
tation and repeat intervention.
Conclusions. In-stent balloon angioplasty for stent restenosis in
native vessels seems to be an effective method in terms of a low
long-term clinical event rate.
(J Am Coll Cardiol 1997;30:186–92)
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Coronary stents have been shown to reduce restenosis com-
pared with balloon angioplasty (1,2), but restenosis still occurs
in 15% to 35% of cases (1–4). The lowest restenosis rates were
observed in focal lesions in large vessels ($3.0 mm) (1,2).
However, the extension of coronary stent indications to more
complex lesions or smaller vessels, or both, produces different,
less favorable results (5). The use of local or systemic pharma-
cologic therapy (6,7), stent coating (8) and radioactive stents
(9,10) may decrease the incidence of restenosis, but while
awaiting these advances, adequate strategies for repeat treat-
ment need to be investigated. Short-term results of intrastent
restenosis treated with balloon angioplasty (11–14); additional
stent implantation; rotational, extraction and directional
atherectomy; and laser treatment have all been reported to be
favorable (15–21), but data regarding the long-term clinical
outcome are not available. The purpose of the present study
was to evaluate the long-term clinical outcome of repeat
percutaneous intervention, mainly balloon angioplasty, for the
treatment of in-stent restenosis.
Methods
Patients. From June 1991 to September 1995, 1,311 con-
secutive patients underwent intracoronary stenting at our
center. Of this cohort, 130 consecutive patients with successful
stent implantation returned with angiographic stent restenosis
and underwent repeat percutaneous intervention. Patients who
had repeat angioplasty for acute or subacute thrombotic stent
occlusion within 1 month after stent implantation were not
included in this series. In six patients the repeat procedure for
in-stent restenosis was unsuccessful (residual diameter stenosis
.30%), and they were excluded from the study. Of these six
patients, two (2%) had elective bypass surgery, three (2%)
were treated medically, and one (1%) had repeat intervention
that was complicated by abrupt vessel closure that led to urgent
bypass surgery and subsequent death due to left ventricular
failure. Therefore, the study included 124 patients (127 ves-
sels) who had successful percutaneous intervention for in-stent
restenosis, and all 124 had clinical follow-up for at least 9
months.
Stenting procedure. Before stent implantation in the orig-
inal lesion, patients were treated with aspirin (325 to 500 mg),
and a bolus of 10,000 U of heparin was given after sheath
insertion, with repeat boluses of 5,000 U of heparin given as
needed to maintain an activated clotting time $250 s. Different
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types of stents were used: The coronary Palmaz-Schatz stent
(Johnson & Johnson Interventional Systems) was the most
commonly used; other stents included Palmaz biliary and renal
stents (Johnson & Johnson Interventional Systems), the
Gianturco-Roubin Flexstent (Cook Inc.), the Micro stent
(Advanced Vascular Engineering Inc., Richmond, Canada),
the Wallstent (Schneider, Bu¨lach, Switzerland), the Wiktor
stent (Medtronic Inc.) and the Cordis stent (Cordis Corp.).
Stents were either hand crimped on a percutaneous translu-
minal coronary angioplasty (PTCA) balloon or were pre-
mounted on a delivery system. After stent deployment, further
dilations were performed within the stent to obtain a near-zero
residual stenosis. Since April 1993, stents have been placed
with intracoronary ultrasound guidance using appropriately
sized balloons inflated at high pressure ($14 atm) for final
in-stent dilations. If necessary, multiple stents were implanted
to cover the entire diseased segment, ensuring minimal overlap
and no gaps. Before the utilization of intravascular ultrasound
guided stenting (April 1993), patients were treated after stent
implantation with intravenous heparin, started 3 to 4 h after
sheath removal and continued until an international normal-
ized ratio of 2.0 to 3.5 was obtained with oral anticoagulation
with warfarin. Warfarin was continued for 1 month with
325 mg of aspirin indefinitely. Since the introduction of
intracoronary ultrasound guided coronary stenting, patients
who met optimal stenting criteria utilized at the time did not
receive any heparin or oral anticoagulant agents after the
procedure. Ticlopidine (250 mg twice daily) was given for
1 month and aspirin (325 mg daily) indefinitely.
Angioplasty procedure for in-stent restenosis. Before re-
peat treatment, patients received aspirin (325 to 500 mg) and
10,000 U of heparin after sheath insertion, with additional
boluses if necessary to maintain an activated clotting time
$250 s. PTCA balloons were positioned within the stented
segment and inflated at high pressure. Restenotic lesions
situated adjacent to the stented segment were treated with
PTCA balloons positioned in part within the stent at lower
inflation pressures. Additional stents were implanted accord-
ing to the protocol in rare cases (13 lesions) of unsatisfactory
PTCA results or for adjacent dissection. Very few restenotic
lesions were treated with rotational atherectomy (4 lesions)
(Rotablator, Heart Technology Inc.) or laser catheter 1.7 to
2.0 mm (2 lesions) (Spectranetics, Colorado Springs), accord-
ing to currently used protocols. The pharmacologic regimen
utilized after repeat intervention for in-stent restenosis con-
sisted of intravenous heparin to maintain an activated clotting
time $200 s for 6 to 12 h after the procedure before sheath
removal and long-term aspirin therapy. In the more recent
period of the study (after April 1993), patients did not receive
postprocedural heparin, and only aspirin (325 mg daily) was
continued long term.
Angiographic analysis. Coronary angiograms were ob-
tained in a routine manner. Patients received intracoronary
isosorbide dinitrate before initial and postprocedural angio-
grams to achieve maximal vasodilation. The vessels and lesions
were analyzed using a computerized quantitative analysis
system (QCA-CMS Version 3.0, MEDIS, Leiden, The Neth-
erlands) according to previously described and validated edge
detection algorithms using the catheter for calibration (22).
Measurements included the interpolated reference diameter,
minimal lumen diameter, percent diameter stenosis and lesion
length and were obtained from the angiograms at baseline,
after stent placement, at restenosis and after repeat treat-
ment. Lesions were characterized according to the modified
American Heart Association/American College of Cardiology
classification (23). The location of the restenotic lesions with
respect to the stented segment was classified as within the stent
body or at the stent edges or affecting both body and edges.
The location of the restenosis with respect to the original
lesion was classified as either at the original lesion site or at a
new site.
Follow-up. Clinical follow-up started after the repeat inter-
vention for in-stent restenosis. For clinical follow-up, patients
were seen at the outpatient clinic, or a direct telephone
interview was performed. Follow-up information was collected
on uniform questionnaires that were included with the medical
records. Adjunctive information was obtained from the refer-
ring physician. Angina symptoms were characterized according
to the Canadian Cardiovascular Society classification. Stress
testing was performed according to the Bruce protocol. In the
event that the exercise test was performed at another institu-
tion, a copy of the report was obtained. For patients who had
clinical events, the clinical follow-up ended at the time of the
event.
Definitions. Primary stent success was defined as stent
implantation in the target lesion with #30% residual stenosis
and without the occurrence of myocardial infarction, urgent
coronary artery bypass graft surgery or death. Procedural
success of the repeat intervention was defined as #30% residual
stenosis at the restenotic lesion site without the occurrence of
myocardial infarction, urgent coronary bypass surgery or
death. Stent restenosis was defined as $50 diameter stenosis at
the stented site or at the proximal or distal adjacent sites.
Diffuse restenosis was defined as a $50% lumen narrowing
$10 mm in length, whereas shorter restenoses were defined as
focal.
A clinical event was defined as death from any cause, Q
wave or non–Q wave myocardial infarction, repeat lesion-
related angioplasty, lesion-related coronary bypass surgery,
recurrence of symptoms and inducible ischemia during stress
testing. Q wave infarction was defined by the presence of a new
pathologic Q wave on the electrocardiogram in association
with creatine kinase elevation twice or more the normal value.
Non–Q wave infarction was present in case of cardiac enzyme
elevation twice the normal value without occurrence of a new
Q wave. Lesion-related bypass surgery or angioplasty included
revascularization of the lesion in which repeat treatment for
in-stent restenosis was performed. Recurrence of symptoms
included the presence of Canadian Cardiovascular Society
class I to IV angina during the follow-up period.
Statistical analysis. Data were analyzed with the SAS
statistical software package. Categoric variables are presented
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as absolute numbers (percent). Continuous variables are pre-
sented as mean value 6 SD. Differences between groups were
evaluated by chi-square analysis or the Fisher exact test for
categoric variables and the Student t test for continuous
variables. The contribution of clinical, angiographic and pro-
cedural variables to the categoric outcome variable (clinical
event after repeat procedure) was evaluated with logistic
regression analysis. First, univariate analysis was performed to
evaluate the contribution of each relevant variable indepen-
dently; then, variables that were found to be significant in
univariate analysis were entered into a stepwise logistic regres-
sion model where selection of variables was achieved in a
(forward and backward) stepwise fashion. The Kaplan-Meier
method was used to generate survival and event-free curves.
Probability values ,0.05 were considered significant.
Results
Original stenting procedure: patient characteristics and
procedural data. Patient and original lesion characteristics are
summarized in Table 1. The original lesions were treated with
a total of 246 stents using 1.9 stents/lesion. In 83% of cases,
Palmaz-Schatz stents were implanted, Wallstents in 6% and
Gianturco-Roubin stents in 4%. The remaining 7% were stents
of various designs (Cordis, Wiktor, AVE-Micro, Palmaz biliary
and Palmaz renal). The mean balloon/artery ratio was 1.14;
high pressure balloon inflations ($14 atm) for stent expansion
were used in 51% of lesions, and intravascular ultrasound
guidance for stent implantation was used in 43%. Oral antico-
agulation was prescribed in 37% of patients, the remaining
patients received antiplatelet therapy only.
Repeat intervention for in-stent restenosis: clinical, angio-
graphic and procedural data. Procedural success of repeat
treatment of in-stent restenosis was achieved in 124 (95%) of
130 patients. Repeat interventional treatment for stent resten-
osis was performed at a mean of 5.9 6 2.9 months (range 2 to
21) after stent implantation. Indications for repeat intervention
were the presence of angina or stress test ischemia, or both, in
90% of patients and angiographic restenosis (defined by $50%
diameter stenosis) without clinical signs of ischemia in 10% of
patients. The angiographic characteristics of restenotic lesions
are shown in Table 2. Restenosis was defined as focal in 62%
of lesions and diffuse (length $10 mm) in 38%. No difference
in the incidence of diffuse versus focal restenosis according to
implantation protocols without and with intracoronary ultra-
sound guidance was observed. Balloon angioplasty was per-
formed using a balloon/artery ratio of 1.16 6 0.19. High
pressure balloon inflations $14 atm were used within the
stented segment in 59% of cases. In 13 patients (10%), an
additional stent was implanted to cover lesions adjacent to the
stent for adjacent dissection or for suboptimal angioplasty
result. Debulking of restenotic plaque before balloon angio-
plasty was performed using rotational atherectomy in four
lesions (3%) and a laser catheter in two (2%).
Quantitative angiographic measurements at baseline, after
the original stenting procedure, at follow-up and after repeat
intervention are shown in Table 3. After repeat intervention,
86% of patients received antiplatelet therapy with aspirin, 10%
received aspirin and ticlopidine, and 4% received oral antico-
agulation.
Long-term outcome of repeat intervention for in-stent
restenosis. As shown in Table 4, clinical follow-up was ob-
tained in all 124 patients (100%) at a mean of 27.4 6 14.7
months (range 9 to 66). Stress test results were available for
88 patients (71%). During the follow-up period, 25 patients
(20%) had one or more events. The mean interval between
repeat procedure and first event was 13.2 6 10.7 months
(range 2 to 32). Target vessel revascularization was performed
in 14 patients (11%), of whom 5 (4%) had coronary bypass
surgery, and 9 (7%) had repeat angioplasty. One patient (1%)
had a Q wave myocardial infarction. In this patient angiogra-
phy was not performed after the event, and he was treated
medically. Two patients (2%) died, one at 3 months after
Table 1. Patient Characteristics, Lesion Morphology and Stenting
Procedure in Original Lesion
Age (yr) 59 6 9.6
Men 114 (92%)
Diabetes 15 (13%)
Ejection fraction (%) 55.8 6 10.6
CCS angina class
I 29 (23%)
II 29 (23%)
III 36 (29%)
IV 30 (25%)
Vessel treated
LAD 50 (39%)
LCx 28 (22%)
RCA 41 (32%)
SVG 8 (7%)
No. of diseased vessels
1 41 (33%)
2 56 (45%)
3 27 (22%)
Lesion type*
A 2 (2%)
B1 33 (26%)
B2 34 (27%)
C 58 (45%)
Lesion length (mm) 12.5 6 7.5
Restenosis 30 (24%)
Stents implanted 246
Stents/lesion 1.9 6 0.5
Multiple stents 83 (65%)
Balloon/artery ratio 1.14 6 0.2
Mean final inflation pressure (atm) 13.2 6 2.7
Final inflation pressure $14 atm 65 (51%)
IVUS guidance 55 (43%)
Oral anticoagulation 45 (37%)
*According to modified American Heart Association/American College of
Cardiology criteria (23). Data presented are mean value 6 SD or number (%) of
patients or lesions, unless otherwise indicated. CCS 5 Canadian Cardiovascular
Society; IVUS 5 intravascular ultrasound; LAD 5 left anterior descending
coronary artery; LCx 5 left circumflex coronary artery; RCA 5 right coronary
artery; SVG 5 saphenous vein graft.
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repeat procedure of congestive heart failure and the other
as a consequence of a liver carcinoma at 12 months after
repeat intervention. Positive stress test results or recurrence
of angina symptoms (Canadian Cardiovascular Society class I
to IV), or both, was observed in eight patients (6%) who
were treated medically. Events occurred in 21 (20%) of 105
patients treated with balloon angioplasty only, 2 (15%) of
13 patients treated with additional stent implantation, 1 (25%)
of 4 patients treated with rotational atherectomy and 1 (50%)
of 2 patients treated with excimer laser. The incidence of
clinical events in the groups treated without (before April
1993) and with intracoronary ultrasound guidance was not
different (p 5 0.3), but multivessel disease was more frequent
in the second group. Angiographic follow-up after repeat
intervention for stent restenosis is not routinely performed at
our institution and was obtained in only 24 patients (19%). Ten
of these patients (42%) had angiographic restenosis ($50%
diameter stenosis). All 10 patients with angiographic restenosis
had recurrence of angina or positive exercise test results, or
both.
Predictors of clinical events after repeat intervention and
cumulative survival. Results of univariate and stepwise re-
gression analysis of predictors of clinical events after repeat
intervention are shown in Table 5. Multivariate predictors
included lesions located in saphenous vein grafts (p , 0.001),
ejection fraction ,30% (p 5 0.02), multivessel disease (p 5
0.01) and interval between stent implantation and first in-stent
restenosis #3 months (p 5 0.01). The occurrence of a clinical
event was observed in 13 (17%) of 77 patients with focal
in-stent restenosis and in 12 (25%) of 47 patients with diffuse
restenosis; diffuse in-stent restenosis was not a significant
predictor of clinical events. Kaplan Meier curves of survival
and event-free survival are shown in Figure 1. Survival at 12
months was 98.4%. Calculated survival free from events such
as myocardial infarction, coronary revascularization, recur-
rence of angina and positive exercise test results was 85.9% at
12 months, 80.3% at 24 months, 74.3% at 36 months and
70.1% at 48 months.
Table 2. Clinical and Angiographic Characteristics of Stent
Restenosis and Repeat Interventional Procedure
Interval from stent implantation (mo) 5.9 6 2.9
Asymptomatic 12 (10%)
CCS angina class I to IV 112 (90%)
Focal restenosis 77 (62%)
Diffuse restenosis ($10 mm) 47 (38%)
Length of restenotic lesion (mm) 11.1 6 8.9
Original lesion site 116 (94%)
Location of stent restenosis
Body 77 (62%)
Edge 9 (8%)
Body1edge 38 (30%)
Repeat treatment
Balloon only 105 (85%)
Stent 13 (10%)
Rotablator 4 (3%)
Laser 2 (2%)
Balloon/artery ratio 1.16 6 0.19
Mean final inflation pressure (atm) 15.5 6 2.3
Final inflation pressure $14 atm 73 (59%)
Data presented are mean value 6 SD or number (%) of patients or lesions.
CCS 5 Canadian Cardiovascular Society.
Table 3. Angiographic Analysis
Original
Lesion
After Stent
Placement Restenosis
After Repeat
Procedure
Mean reference diameter (mm) 3.04 6 0.48 3.11 6 0.37 2.93 6 0.45 3.09 6 0.50
Minimal lumen diameter (mm) 0.85 6 0.52 3.21 6 0.48* 0.90 6 0.49† 2.91 6 0.39‡§
Diameter stenosis (%) 72 6 19 23 6 10* 69 6 17† 6 6 13‡§
Acute lumen gain (mm) 2.36 6 0.44 2.01 6 0.42§
Late loss (mm) 2.31 6 0.62
*p , 0.001 versus original lesion. †p , 0.001, §p , 0.02 versus after stent placement. ‡p , 0.01 versus restenosis. Data
presented are mean value 6 SD.
Table 4. Follow-Up Results
Follow-up (mo) 27.4 6 14.7
Clinical follow-up obtained 124 (100%)
Exercise test obtained 88 (71%)
Event free 99 (80%)
Any event 25 (20%)
In patients with focal restenosis 13 (17%)*
In patients with diffuse restenosis 12 (25%)*
Any event in 105 patients treated with balloon
angioplasty only
21 (20%)
Target vessel revascularization 14 (11%)
CABG 5 (4%)
Angioplasty 9 (7%)
Death 2 (2%)
Myocardial infarction 1 (1%)
Recurrence of symptoms† and/or positive
exercise test results
8 (6%)
Interval between repeat procedure and event 13.2 6 10.7
Angiographic follow-up 24 (19%)
$50% diameter stent stenosis 10 (42%)
Diffuse ($10 mm) 5 (50%)
*Percent of patients with that type of restenosis. †Canadian Cardiovascular
Society class I to IV. Data presented are mean value 6 SD or number (%) of
patients. CABG 5 coronary artery bypass graft surgery.
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Discussion
Comparison with other studies. The results of the present
study demonstrate that the treatment of in-stent restenosis has
a high immediate success rate and a favorable long-term
clinical outcome. Procedural success was achieved in 95% of
patients by obtaining #30% residual stenosis. These results are
comparable to other reports. Baim et al. (11) and Macander et
al. (13) reported immediate success rates of 100% and 97%,
respectively, for balloon angioplasty for the treatment of stent
restenosis. In the present study, long-term clinical follow-up
was obtained in all of a consecutive series of 124 patients at a
mean of 27 6 14 months after repeat intervention. Only 20%
of patients had one or more events (11% target lesion revas-
cularization, 2% death and 7% ischemia treated medically).
Event-free survival was 86% at 12 months, 80% at 24 and 74%
at 36 months. In the subgroup of 105 patients treated for stent
restenosis with balloon angioplasty only, the event rate was
identically 20% (21 patients). To our knowledge, there are no
published long-term follow-up studies for direct comparison.
The results of the present study compare favorably with
previous studies (11–14) reporting angiographic restenosis
after intrastent balloon redilation to vary between 31% and
54%. However, in these studies the true angiographic resten-
osis rate might have been somewhat lower because symptom-
atic patients were restudied selectively. Yokoi et al. (24)
evaluated angiographic follow-up data for 82 patients who had
intrastent restenosis and were treated with repeat balloon
angioplasty. Of these patients, 62 returned for angiographic
follow-up, and angiographic restenosis was 37%. Recurrent
restenosis was 85% in the small subgroup of patients who were
treated for diffuse in-stent restenosis. In the present study,
where clinical and not angiographic restenosis was evaluated,
diffuse restenosis was not predictive of recurrent clinical events
after repeat intervention. The reason for the discrepancy
between the studies is not clear. However, two critical issues
have to be kept in perspective when comparing retrospective
data: 1) Factors that have traditionally been shown to influence
the restenosis rate in primary lesions, such as vessel size,
original lesion length and the final result achieved after
intervention, are not accounted for in such comparisons; and
2) subgroup analysis in small patient series lack the statistical
power to generalize conclusions. Furthermore, a comparison
of clinical with angiographic restenosis might be misleading,
but other studies for comparison are not available.
Figure 1. Kaplan-Meier curves of cumulative survival and
event-free survival.
Table 5. Analysis of Predictors of Clinical Events After
Repeat Intervention
p Value* OR (95% CI)
Diabetes mellitus 0.68
Ejection fraction ,30% 0.02 0.95 (0.91–0.99)
Repeat intervention in SVG ,0.001 6.42 (2.45–16.88)
Vessel segment 0.09
Multivessel disease 0.01 5.04 (1.39–18.22)
Complete revascularization 0.54
More complex lesion before stent
placement*
0.51
Restenosis lesion before stent
placement
0.14
Lesion length before stent placement 0.53
Reference diameter before stent
placement
0.27
Multiple stents 0.92
Interval between stent placement
and repeat intervention #3 mo
0.01 5.77 (1.43–23.34)
Diffuse restenosis ($10 mm) 0.09
Restenotic lesion length (mm) 0.17
Location of restenosis (body vs. edge
vs. body1edge)
0.34
*p , 0.05 statistically significant. †According to modified American Heart
Association/American College of Cardiology classification. CI 5 confidence
interval; OR 5 odds ratio; SVG 5 saphenous vein graft.
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A comparison of the outcome of repeat procedures for
restenosis after balloon angioplasty without stents and for
in-stent restenosis is hampered because major pathologic
differences have been described in the restenotic process after
balloon angioplasty and coronary stenting (12,17,25–27). How-
ever, the present study suggests that repeat balloon dilation for
in-stent restenosis has a favorable outcome compared with
repeat treatment of balloon angioplasty restenosis, where
recurrent restenosis is reported to occur in 31% to 50% of
patients (28,29).
Predictors of clinical events after treatment of in-stent
restenosis. Significant predictors of long-term combined clin-
ical events after repeat intervention for in-stent restenosis were
lesion located in saphenous vein grafts, ejection fraction
,30%, presence of multivessel disease and first in-stent re-
stenosis occuring #3 months after stent implantation (Table
5). Saphenous vein grafts have been associated, especially in
the presence of diffuse disease, with a higher restenosis rate
after any type of percutaneous intervention than native vessels
(30,31). Stenting of restenotic vein grafts has been associated
with a restenosis rate of 70% (32). In the present study, seven
(87%) of eight patients developed recurrence of clinical events
after treatment of in-stent restenosis of a saphenous vein graft.
However, the number of saphenous vein graft lesions is too
small to draw any final conclusions.
Patients with ,30% ejection fraction and with multivessel
disease had a significantly higher incidence of long-term
clinical events. These findings are similar to those reported for
initial percutaneous interventions (2,23,30). A short, #3-
month interval between stent implantation and first restenosis
predicted the occurrence of clinical events suggestive of a
highly aggressive restenotic process. Similar results have been
found for balloon angioplasty without stenting where the only
significant predictor of a second restenosis was a ,3-month
interval between the first and second treatment (28,33). The
presence of longer lesions, smaller vessel diameter, implanta-
tion of multiple stents, stent implantation in restenotic lesions,
patients with diabetes and the presence of diffuse stent resten-
osis did not predict recurrent clinical restenosis; however, the
small number of patients in these subgroups does not permit
general conclusions.
Device synergy in the treatment of in-stent restenosis.
In-stent balloon redilation has been shown (11,13) to be an
effective and safe method for treatment of in-stent restenosis.
The degree of lumen enlargement after redilation of in-stent
restenosis appears to be primarily due to compression or
extrusion of intimal hyperplasia through the stent struts, or
both, rather than to further stent expansion (12). This mech-
anism holds true in the era of high pressure stent optimization
(34), which maximizes the probability of complete stent expan-
sion during the first procedure. If optimal expansion was not
achieved initially because of calcium or high plaque volume, it
is unlikely that further dilation at follow-up will increase stent
expansion. Therefore, it could be argued that balloon angio-
plasty alone will not achieve the maximal possible lumen
enlargement. This is supported by the finding that the acute
lumen gain in this study after repeat procedure was 2.01 mm,
which is acceptable but still significantly lower than that
achieved after the original stenting procedure (2.36 mm, p ,
0.05). This argument supports the theoretic justification to
debulk the mass of intimal hyperplasia within the stent to
facilitate lumen enlargement with balloon angioplasty. In fact,
several investigators have reported the use of various debulk-
ing strategies for stent restenosis. Directional atherectomy has
been used in small series of patients (17,18). Rotational
atherectomy (16), extraction atherectomy (19), excimer laser
angioplasty (20,21) and additional stenting have been used
with or without additional balloon angioplasty, and good
results in terms of lumen enlargement have been reported.
However, the impact of these approaches on the degree of
intimal regrowth is still to be determined. Intravascular ultra-
sound examination of restenotic stents might be useful to
determine specific treatment strategies, such as balloon for
underexpanded stents, debulking for diffuse intimal prolifera-
tion and additional stents for adjacent disease or stent com-
pression. The results in terms of recurrence of clinical events
might have been influenced favorably by a vessel size .3.0 mm
and a relatively short lesion length of 12.5 mm of the originally
treated lesion. The extension of stent indications to smaller
vessels and longer lesions might produce a different outcome
of repeat intervention for stent restenosis.
Additional stenting. The treatment of stent ingrowth by
implantation of an additional stent within the stent has been
proposed to prevent further protrusion of restenotic plaque
(15), but no data are available concerning eventual new,
reactive intimal hyperplasia. In the present study, additional
stenting was performed in 10% of cases and only to cover
lesions adjacent to the stented segment, for adjacent dissec-
tions or for recoil after in-stent balloon redilation. In this
subgroup, the immediate success rate (100%) and long-term
clinical outcome did not differ from patients treated with
in-stent angioplasty only.
Limitations of the study. Several important limitations
should be noted when interpreting the results of this study. It
is a retrospective analysis; different designs of stents in the
single patient were used in 17% of cases; and the low (19%)
angiographic follow-up rate after the repeat procedure pre-
vents the direct comparison of long-term clinical outcome with
angiographic findings. In addition, the low event rate in this
cohort undermines the ability to draw strong conclusions
regarding predictors of clinical events. Despite these limita-
tions, to our knowledge, this is the first large study to report the
long-term outcome of this increasingly important patient pop-
ulation. The mechanisms that led to first and second in-stent
restenosis were not clarified in this study because intravascular
ultrasound was not performed before repeat intervention for
in-stent restenosis.
Conclusions. Stent restenosis is an increasing problem.
In-stent balloon angioplasty in native vessels appears to be a
safe and effective method in terms of a low long-term clinical
event rate in the treatment of this subset of patients. Alterna-
tive approaches should be compared with the present results.
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